Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.
Waning factor VIII levels mean the durability question is still unanswered.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.
The group’s latest data cut with XMT-1536 in ovarian cancer raises several red flags.
The group has blamed placebo “overperformance” on a high proportion of less-sick patients.